Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.
Download Issue
A couple of days after we added Cardinal Health (CAH) to our portfolio two weeks ago, the company announced it had entered into an agreement with Navidea Biopharmaceuticals to market its radioactive cancer diagnostic product throughout North America. The two companies had already been working together, splitting sales proceeds… Read More
Download Issue
By the end of November nearly all of our Open Trades positions were sporting positive returns, setting the stage for what should be a very profitable December. Read More
Download Issue
According to conventional wisdom, Donald Trump’s victory was supposed to suppress gun sales for companies like Sturm, Ruger & Co. (RGR) because the odds of stricter gun control laws should be considerably diminished under an NRA-friendly administration. Sales of firearms were running high in the months leading up to the… Read More
Download Issue
Our most recent addition to the portfolio has only been open for a few days, so there isn’t much more to say about since last week’s alert. We bought USANA Health Sciences (USNA) a week after its stock split 2 for 1, and so far its share price continues… Read More
Download Issue
Until Nov. 8, the day of the U.S. presidential election, shares of Delphi Automotive (DLPH) were zooming up the charts after the company reported another solid set of quarterly numbers the week before. But Donald Trump’s unexpected victory sent DLPH tumbling on fears that possible trade wars with Mexico… Read More
Download Issue
We bought GNC Holdings (GNC) on Nov. 3 after its share price plunged 40% in late October on the heels of a disappointing quarterly earnings report that missed on both the top and bottom lines. We felt the selling that followed that news was excessive, setting the stage for a… Read More
We are closing out our position in Ruth’s Hospitality for an annualized return of 60%! Read More
USANA Health Sciences develops and makes science-based nutritional and personal care products. USANA also ranks 33rd among all 6,000+ stocks evaluated by our Rapids Profits Matrix for its... Read More
We are selling our position in Juno Therapeutics (JUNO).Last week Juno, a cancer immunotherapy drug maker, announced that it is placing its Phase 2 clinical trial of JCAR015 on hold as the result of the death of one of its trial subjects, and the likely death of a second… Read More
Of all the companies in the S&P 500 Index, only one of them currently earns a perfect score of ‘10’ from my IDEAL Stock Rating System, and that one is Cardinal Health. A month ago its share price took a 15% hit after the company released quarterly earnings that beat expectations, but... Read More